OTCMKTS:BIOYF BioSyent (BIOYF) Stock Price, News & Analysis $7.81 -0.01 (-0.06%) As of 02/21/2025 01:56 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesShort Interest About BioSyent Stock (OTCMKTS:BIOYF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BioSyent alerts:Sign Up Key Stats Today's Range$7.81▼$7.8150-Day Range$7.38▼$8.4252-Week Range$5.93▼$8.90Volume180 shsAverage Volume4,348 shsMarket CapitalizationN/AP/E Ratio38.35Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.Read More… BioSyent Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreBIOYF MarketRank™: BioSyent scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for BioSyent. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of BioSyent is 38.35, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.82.Price to Earnings Ratio vs. SectorThe P/E ratio of BioSyent is 38.35, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.77.Read more about BioSyent's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverBioSyent has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioSyent has recently increased by 225.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioSyent does not currently pay a dividend.Dividend GrowthBioSyent does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverBioSyent has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioSyent has recently increased by 225.00%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News SentimentN/A News SentimentBioSyent has a news sentiment score of 2.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for BioSyent this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioSyent insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.08% of the stock of BioSyent is held by institutions.Read more about BioSyent's insider trading history. Receive BIOYF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOYF Stock News HeadlinesBioSyent Declares First Quarter 2025 DividendJanuary 30, 2025 | globenewswire.comFAX Capital Files Early Warning Report Regarding Disposition of Common Shares of BioSyent Inc.January 6, 2025 | globenewswire.comWhy 2026 will be a disaster for many AmericansWall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin says stocks could crash in 2026—he's even calling the exact month and most likely day it will start. No one on or off Wall Street has been more accurate calling the bull and bear turns of the past 7 years. And now, Chaikin is calling the crash of 2026.February 24, 2025 | Chaikin Analytics (Ad)BioSyent Announces Renewal of Normal Course Issuer BidDecember 16, 2024 | globenewswire.comFAX Capital Files Early Warning Report Regarding Disposition of Common Shares of BioSyent Inc.November 25, 2024 | globenewswire.comBioSyent Releases Financial Results for Q3 and YTD 2024November 20, 2024 | globenewswire.comBioSyent Declares Fourth Quarter 2024 DividendNovember 20, 2024 | globenewswire.comBioSyent Schedules Q3 and YTD 2024 Earnings Release for November 20, 2024November 13, 2024 | globenewswire.comSee More Headlines BIOYF Stock Analysis - Frequently Asked Questions How have BIOYF shares performed this year? BioSyent's stock was trading at $7.6425 at the beginning of the year. Since then, BIOYF stock has increased by 2.1% and is now trading at $7.8050. View the best growth stocks for 2025 here. How do I buy shares of BioSyent? Shares of BIOYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Ex-Dividend for 12/16 Dividend11/29/2024Dividend Payable12/16/2024Today2/24/2025Ex-Dividend for 3/14 Dividend2/28/2025Dividend Payable3/14/2025Next Earnings (Estimated)5/14/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:BIOYF CUSIPN/A CIKN/A Webwww.biosyent.com Phone(905) 206-0013FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio38.35 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (OTCMKTS:BIOYF) was last updated on 2/24/2025 by MarketBeat.com Staff From Our PartnersWhy 2026 will be a disaster for many AmericansWall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredThe DOGE Shock: Nine Stocks to Take Advantage of Elon’s Next MoveElon Musk - the billionaire leader of Tesla, SpaceX, Neuralink and xAI - has launched his Department of Govern...Altimetry | SponsoredPresident Trump Boosts Your 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioSyent Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioSyent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.